RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close.
The consensus EPS Estimate is $1.56 (-11.4% Y/Y) and the consensus Revenue Estimate is $5.44B (+3.0% Y/Y).
Over the last 2 years, GILD has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 12 downward. Revenue estimates have seen 5 upward revisions and 7 downward.
The FDA has approved GlaxoSmithKline’s (NYSE:GSK) supplemental marketing application for Zejula (niraparib) for the maintenance treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
The PARP inhibitor was first approved in the U.S. in March 2017 for women with recurrent ovarian cancer.
Shares up 1% after hours.
NeoGenomics (NASDAQ:NEO) has filed a preliminary prospectus for a $150M offering of convertible senior notes due 2025. Price, yield and terms have yet to be announced.
The company is also offering $100M of its common stock pursuant to a separate prospectus. In addition, the underwriters are offering $40M of stock borrowed from third parties to use in hedging transactions (short positions) by some of the note buyers.
Shares down 5% after hours.
Moderna (NASDAQ:MRNA) is up 1.8% postmarket after getting a Street-high price target from BMO Capital Markets, which started the stock with an Outperform rating.
That’s based on advancing its coronavirus vaccine candidate.
The firm’s set a price target of $83, implying 79% upside.
The success of the candidate isn’t certain, of course, but BMO sees a high probability that Phase 1 results will show the generation of neutralizing antibody titers when reported in June – and a meaningful number of volunteers generating antibodies is a near-term value driver.
Government funding and promising results from later-stage candidates help validate the potential, analyst George Farmer says.
SIGA Technologies (NASDAQ:SIGA) jumped 7% post-market after BARDA exercised a $101.3 million option in its contract for oral TPOXX for the treatment of smallpox (tecovirimat).
Deliveries expected to start in 2Q and be completed by April of next year.
SIGA’s full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise.
CEO said, “the ongoing COVID-19 pandemic has dramatically underscored the importance of national preparedness. The exercise emphasizes the critical value of our smallpox anti-viral treatment in that effort, and underscores SIGA’s commitment to working with BARDA and the Office of the Assistant Secretary for Preparedness and Response (ASPR) to protect against the threat of a potential smallpox outbreak or bioterror attack.”
SIGA reported ~$27M in revenue in 2019, $477M in 2018 and $12.3M in 2017.
